IMGN Stock Overview ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
ImmunoGen, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for ImmunoGen Historical stock prices Current Share Price US$31.23 52 Week High US$31.25 52 Week Low US$3.61 Beta 1.17 1 Month Change 4.94% 3 Month Change 98.16% 1 Year Change 617.93% 3 Year Change 196.58% 5 Year Change 452.74% Change since IPO 228.74%
Recent News & Updates
ImmunoGen Files Form 15 Feb 23 ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.
Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means Feb 09
President notifies of intention to sell stock Feb 07
Insider notifies of intention to sell stock Jan 18 See more updates
ImmunoGen Files Form 15 Feb 23 ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.
Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means Feb 09
President notifies of intention to sell stock Feb 07
Insider notifies of intention to sell stock Jan 18
ImmunoGen, Inc.'s (NASDAQ:IMGN) Intrinsic Value Is Potentially 40% Above Its Share Price Jan 09
Forecast breakeven date pushed back to 2024 Dec 31
There's Reason For Concern Over ImmunoGen, Inc.'s (NASDAQ:IMGN) Massive 95% Price Jump Dec 22
Insider notifies of intention to sell stock Dec 18
ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH Dec 11
FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer Dec 05
Insider exercised options and sold US$3.0m worth of stock Dec 03 AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion. Dec 01
New major risk - Share price stability Dec 01
Price target increased by 10% to US$25.39 Nov 30 AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion. Nov 30
Insider recently sold US$1.5m worth of stock Nov 10
Forecast breakeven date moved forward to 2023 Nov 03
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 03
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer Oct 28
Insider exercised options and sold US$1.9m worth of stock Oct 19
Insider recently sold US$1.3m worth of stock Sep 20 ImmunoGen, Inc. Announces Executive Changes
Insider notifies of intention to sell stock Sep 18
President recently sold US$17m worth of stock Aug 06 Immunogen, Inc. Reaffirmes Revenue Guidance for 2023 Aug 02
Forecast breakeven date moved forward to 2024 Aug 01
ImmunoGen, Inc. Announces Executive Changes Aug 01
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Jul 31
Price target increased by 8.0% to US$19.00 Jul 21
Price target increased by 13% to US$16.20 Jun 10
ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress Jun 09
ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE Jun 05
Consensus revenue estimates increase by 80% May 05
ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer May 04
Price target increased by 18% to US$14.10 May 03
Forecast to breakeven in 2025 May 01
First quarter 2023 earnings: EPS and revenues exceed analyst expectations Apr 30
No longer forecast to breakeven Mar 10
Consensus EPS estimates upgraded to US$0.80 loss, revenue downgraded Mar 08
Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021) Mar 02
Forecast to breakeven in 2025 Mar 01
Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs Jan 05 ImmunoGen, Inc. Announces Executive Changes
ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH Dec 13
ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer Nov 22
NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm) Nov 19 Shareholder Returns IMGN US Biotechs US Market 7D 6.6% -6.5% -4.0% 1Y 617.9% 1.3% 24.0%
See full shareholder returns
Return vs Market: IMGN exceeded the US Market which returned 20.6% over the past year.
Price Volatility Is IMGN's price volatile compared to industry and market? IMGN volatility IMGN Average Weekly Movement 24.0% Biotechs Industry Average Movement 10.7% Market Average Movement 6.4% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.2%
Stable Share Price: IMGN's share price has been volatile over the past 3 months.
Volatility Over Time: IMGN's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate.
Show more ImmunoGen, Inc. Fundamentals Summary How do ImmunoGen's earnings and revenue compare to its market cap? IMGN fundamental statistics Market cap US$8.36b Earnings (TTM ) -US$73.52m Revenue (TTM ) US$287.61m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IMGN income statement (TTM ) Revenue US$287.61m Cost of Revenue US$211.62m Gross Profit US$76.00m Other Expenses US$149.52m Earnings -US$73.52m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -0.27 Gross Margin 26.42% Net Profit Margin -25.56% Debt/Equity Ratio 12.8%
How did IMGN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/02/12 00:57 End of Day Share Price 2024/02/12 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ImmunoGen, Inc. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ling Wang Brean Capital John Newman Canaccord Genuity Mara Goldstein Cantor Fitzgerald & Co.
Show 17 more analysts 
